Flumatinib mesylate Catalog No.:M9593-10 NSC-348884 also disrupts oligomer formation

NSC-348884 also disrupts oligomer formation and induces apoptosis in human cancer cells

A small molecule inhibitor of polycomb repressive complex 1 inhibits ubiquitin signaling at DNA double-strand breaks

Epub 2015 Mar 28

SD-208 reduces the development and progression of melanoma bone metastases

Flumatinib mesylate Catalog No.:M9593-10 NSC-348884 also disrupts oligomer formationFlumatinib, also known as HHGV678 , is a selective inhibitor of BCR ABL PDGFR KIT. Flumatinib is currently in Phase I and II clinical trials in China for the treatment of chronic myelogenous leukemia (CML). Flumatinib effectively overcomes drug resistance of certain KIT mutants. Flumatinib mesylate can reduce the expression of C MYC, HIF 1 and VEGF in U266 cell line in a time and dose dependent manners. Product information CAS Number: 895519 91 2